<![CDATA[Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia]]>

ConferenceteclistamabNeutral

AI Analysis

Summary

Dr. Meletios A. Dimopoulos discussed the potential role of bispecific antibodies, such as teclistamab, in treating relapsed Waldenström macroglobulinemia. This is a conference discussion on clinical applications without new data or regulatory decisions.

Importance:2/10

Sentiment:

0.00

bispecific antibodiesWaldenström macroglobulinemiarelapsed diseaseoncologyclinical discussion

Read the original article

Published by Cancer Network on September 23, 2026 6:00 PM

Read Original